41,268 Shares in Medpace Holdings, Inc. $MEDP Purchased by Legal & General Group Plc

Legal & General Group Plc acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the second quarter, HoldingsChannel reports. The firm acquired 41,268 shares of the company’s stock, valued at approximately $21,855,000.

A number of other hedge funds have also recently added to or reduced their stakes in MEDP. Johnson Financial Group Inc. purchased a new stake in Medpace in the second quarter valued at approximately $27,000. Elyxium Wealth LLC acquired a new position in shares of Medpace during the 4th quarter valued at $30,000. Jones Financial Companies Lllp acquired a new position in shares of Medpace during the 2nd quarter valued at $30,000. Allied Private Wealth LLC purchased a new stake in Medpace during the 2nd quarter worth $31,000. Finally, Kilter Group LLC purchased a new stake in Medpace during the 2nd quarter worth $31,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $600.65 on Friday. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The stock’s 50-day simple moving average is $565.33 and its 200-day simple moving average is $494.55. The firm has a market cap of $16.77 billion, a price-to-earnings ratio of 35.21, a PEG ratio of 2.68 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the prior year, the business posted $3.10 earnings per share. Medpace’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Insider Transactions at Medpace

In other Medpace news, CFO Kevin M. Brady sold 3,400 shares of the stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $625.24, for a total transaction of $2,125,816.00. Following the transaction, the chief financial officer directly owned 12,830 shares in the company, valued at $8,021,829.20. This represents a 20.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Fred B. Davenport, Jr. sold 7,283 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the transaction, the director directly owned 3,798 shares of the company’s stock, valued at approximately $2,302,157.70. This represents a 65.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 133,821 shares of company stock valued at $81,748,135 over the last ninety days. 20.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on MEDP. Mizuho raised their price objective on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. BMO Capital Markets upped their price target on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Royal Bank Of Canada increased their price objective on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Finally, Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and boosted their target price for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, Medpace presently has a consensus rating of “Hold” and a consensus price target of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.